BriaCell Therapeutics Files 8-K Report
Ticker: BCTXZ · Form: 8-K · Filed: Jun 18, 2025 · CIK: 1610820
Sentiment: neutral
Topics: disclosure, financials, corporate-actions
Related Tickers: BCTX
TL;DR
BriaCell Therapeutics filed an 8-K on June 16, 2025, covering Reg FD and financials.
AI Summary
On June 16, 2025, BriaCell Therapeutics Corp. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits. The company, formerly known as Ansell Capital Corp. until June 13, 2014, is incorporated in British Columbia and operates in the Pharmaceutical Preparations sector.
Why It Matters
This 8-K filing provides an update on BriaCell Therapeutics Corp.'s regulatory disclosures and financial reporting, which is important for investors to monitor the company's status.
Risk Assessment
Risk Level: low — This filing is a routine disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- June 16, 2025 (date) — Date of earliest event reported
- June 13, 2014 (date) — Date of former company name change
FAQ
What is the primary purpose of this 8-K filing for BriaCell Therapeutics Corp.?
The primary purpose of this 8-K filing is for Regulation FD disclosures and to report financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 16, 2025.
What was BriaCell Therapeutics Corp. formerly known as, and when did the name change occur?
BriaCell Therapeutics Corp. was formerly known as Ansell Capital Corp., and the name change occurred on June 13, 2014.
In which jurisdiction is BriaCell Therapeutics Corp. incorporated?
BriaCell Therapeutics Corp. is incorporated in British Columbia.
What is BriaCell Therapeutics Corp.'s Standard Industrial Classification (SIC) code and industry?
BriaCell Therapeutics Corp.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 regarding BriaCell Therapeutics Corp. (BCTXZ).